UNSPSC 51392409: Dobutamine lactobionate

This classification denotes an adrenergic agent with the molecular formula C18H23NO3.C12H22O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CP0YC140T9, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+/-)-, 4-o-.beta.-d-galactopyranosyl-d-gluconate (salt), but more generally known as dobutamine lactobionate, which bears US NIH Compound Identifier 3038222.

European Medicines Agency schedules dobutamine lactobionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06343MIG. Most nations, for tariff purposes, schedule dobutamine lactobionate under HS 29222900. SMILES: CC(CCC1CCC(CC1)O)NCCC2CCC(C(C2)O)O.C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)O)O)O)O)O)O)O.

UNSPSC 51392409 Dobutamine lactobionate is a Commodity code that covers a specific pharmaceutical product used in acute care settings, though recent state and local opportunities tagged under this code show minimal alignment with the code's nominal scope. The solicitations reflect a broader state and local market for pharmaceutical procurement and pharmacy benefit management services rather than dobutamine specifically. Issuing bodies include county health departments and state human services agencies pursuing pharmaceutical supply agreements and pharmacy program infrastructure.

Recent activity spans Florida and Texas. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, response deadline July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity, negotiated net pricing models, and outcomes-based agreements. The code shows limited recent activity directly under dobutamine lactobionate; state and local procurement offices appear to tag broader pharmaceutical and pharmacy services work to this commodity code, suggesting classification misalignment rather than active dobutamine-specific demand.